Elcelyx's NewMet could fill diabetes niche
This article was originally published in Scrip
Executive Summary
If Elcelyx Therapeutics's hypothesis about how metformin works in type 2 diabetes patients is confirmed in an ongoing Phase IIb clinical trial for the San Diego company's delayed-release metformin product called NewMet, the drug could become a viable therapy for millions of patients who are unable to take the widely prescribed generic medicine.